December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

241.31 +6.04 (+2.57%)
Streaming Delayed Price Updated: 1:35 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
The Fear Gauge Ascendant: VIX Hits 26 as Geopolitical Storms and 'Higher-for-Longer' Reality Grip Markets
The CBOE Volatility Index (VIX), Wall Street’s premier measure of expected stock market volatility, climbed to a reading of 26.15 this week, marking its highest sustained level in nearly two years. As... 
Via MarketMinute
Topics Derivatives Economy Stocks
News headline image
If You Only Own Tech Stocks, Jim Cramer Has a Blunt Warning for You in 2026 ↗
CNBC commentator Jim Cramer sees value in the artificial intelligence (AI) realm beyond the technology sector. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits the Psoriasis Market
In a landmark decision for the dermatology sector, the U.S. Food and Drug Administration (FDA) has officially approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral peptide for the treatment of... 
Via MarketMinute
News headline image
Johnson & Johnson (JNJ) Forecast: Extended Rally Signals Patience for Buyers ↗
Via Talk Markets
Johnson & Johnson (NYSE:JNJ): A Dividend King Built for Sustainable Passive Income ↗
Via Chartmill
News headline image
1 Dividend ETF That Could Turn $500 Monthly Into a $725,000 Portfolio That Pays $21,750 Annually ↗
Patience can pay off with this high-yield dividend ETF. 
Via The Motley Fool
Topics ETFs
News headline image
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie ↗
FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competition in treatment options. 
Via Benzinga
News headline image
2 Reasons to Buy Johnson & Johnson Stock Like There's No Tomorrow ↗
This stock is one to own during any market environment. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown
The pharmaceutical giant AbbVie (NYSE: ABBV) experienced a sharp decline on Wednesday, March 18, 2026, as its stock price tumbled to its lowest level since mid-2025. Shares of the Illinois-based... 
Via MarketMinute
Topics ETFs Economy Intellectual Property
News headline image
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
2 Stocks That Could Create Lasting Generational Wealth ↗
These investments could help you sleep peacefully at night. 
Via The Motley Fool
Topics World Trade
News headline image
The $40 Billion Pivot: Kimberly-Clark and Kenvue Merger Redefines the Consumer Staples Landscape
In a move that signals a seismic shift in the global consumer goods sector, Kimberly-Clark (NYSE:KMB) is charging forward with its landmark $48.7 billion enterprise value acquisition of consumer health... 
Via MarketMinute
Topics Artificial Intelligence Lawsuit
News headline image
Your Tax Refund Will Probably Be Bigger This Year. Here's What to Do With It. ↗
There are still reliable stocks to consider for investing your tax refund this year. 
Via The Motley Fool
Topics Economy Retirement
News headline image
Stryker Corporation (SYK): Navigating Innovation and Resilience in the Wake of a Digital Crisis
As of March 16, 2026, the medical technology landscape is grappling with a stark reminder of the vulnerabilities inherent in the digital shift of healthcare. Stryker Corporation (NYSE: SYK), a global... 
Via Finterra
Topics Earnings Economy Hacking
News headline image
Johnson & Johnson’s Trial In Early-Stage Bladder Cancer Yield Positive Safety Results ↗
The study also demonstrated complete and durable responses in patients with recurrent intermediate-risk disease, along with encouraging recurrence-free outcomes in high-risk disease, the company said. 
Via Stocktwits
News headline image
Flight to Quality: JPMorgan and Eli Lilly Emerge as Defensive Anchors Amid Geopolitical Storm
In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Best Dividend Stocks to Buy and Hold Forever ↗
They are relatively safe wealth compounders. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 No-Brainer S&P 500 Vanguard ETF to Buy Right Now for Less Than $1,000 ↗
During times of uncertainty, this ETF makes a great buy. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon... 
Via Finterra
Topics ETFs Intellectual Property
News headline image
Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
From Johnson & Johnson
Via Business Wire
News headline image
End of an Era: West Pharmaceutical Shares Slide as Longtime CEO Eric Green Announces Retirement
Shares of West Pharmaceutical Services (NYSE: WST) tumbled 5.7% on Tuesday following the announcement that Eric Green, the company’s President, Chief Executive Officer, and Chair of the Board, intends... 
Via MarketMinute
Topics Economy Retirement
News headline image
Cracks in the Bull Case: S&P 500 Breaches Key Support as Institutional Distribution Takes Hold
The multi-year bull market that defined the mid-2020s is facing its sternest test yet. On March 11, 2026, the S&P 500 index decisively breached the critical 6,764 support level, a technical floor that... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Safe Haven in a Storm: Healthcare Leads Markets as Geopolitical Tensions Spark Defensive Rotation
On a day marked by deepening global uncertainty and a sharp spike in energy costs, the healthcare sector emerged as the primary beneficiary of a massive "risk-off" migration by institutional investors.... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Quiet Outperformance From an Overlooked Dividend ETF ↗
Via MarketBeat
News headline image
2 No-Brainer Dividend Stocks to Buy in 2026 ↗
Their futures look bright, and their dividends are safe. 
Via The Motley Fool
Topics Intellectual Property
News headline image
These 7 Elite Dividend Stocks Pay $114 Billion Annually, Combined, to Their Shareholders ↗
Seven of Wall Street's most influential businesses are doling out between $11.9 billion and $27.1 billion to their investors each year. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
FDA Clears Johnson & Johnson's Multiple Myeloma Combo Drug After Strong Survival Results ↗
FDA approves Johnson & Johnson's Tecvayli with Darzalex Faspro for multiple myeloma after strong Phase 3 survival results. 
Via Benzinga
News headline image
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
EQNX::TICKER_START (NNASDAQ:HELP),(CBOE:HELP),(NASDAQ:ACHC),(NYSE:JNJ),(NASDAQ:BWAY),(NASDAQ:AIFF) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
2 Top Defensive ETFs That Prioritize Stability Over Excitement ↗
If you're worried about downside risk right now, here are two smart choices. 
Via The Motley Fool
Topics Artificial Intelligence ETFs World Trade
News headline image
ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth
In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise... 
Via MarketMinute
Topics Earnings Economy
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.